ETON
Price:
$12.66
Market Cap:
$337.20M
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in c...[Read more]
Industry
Biotechnology
IPO Date
2018-11-13
Stock Exchange
NASDAQ
Ticker
ETON
According to Eton Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -36.29%. This represents a change of 277.26% compared to the average of -9.62% of the last 4 quarters.
The mean historical ROE of Eton Pharmaceuticals, Inc. over the last ten years is -80.02%. The current -36.29% ROE has changed -54.65% with respect to the historical average. Over the past ten years (40 quarters), ETON's ROE was at its highest in in the June 2023 quarter at 27.26%. The ROE was at its lowest in in the September 2020 quarter at -468.59%.
Average
-80.02%
Median
-58.99%
Minimum
-184.06%
Maximum
-6.05%
Discovering the peaks and valleys of Eton Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 345.35%
Maximum Annual ROE = -6.05%
Minimum Annual Increase = -91.91%
Minimum Annual ROE = -184.06%
Year | ROE | Change |
---|---|---|
2023 | -6.05% | -91.91% |
2022 | -74.80% | 345.35% |
2021 | -16.80% | -90.88% |
2020 | -184.06% | 7.65% |
2019 | -170.99% | 253.02% |
2018 | -48.44% | -17.90% |
The current ROE of Eton Pharmaceuticals, Inc. (ETON) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.55%
5-year avg
-90.54%
10-year avg
-80.02%
Eton Pharmaceuticals, Inc.’s ROE is less than Connect Biopharma Holdings Limited (7.21%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Nuvation Bio Inc. (-108.68%), less than Eledon Pharmaceuticals, Inc. (21.51%), less than Eliem Therapeutics, Inc. (0%), less than Inhibrx Biosciences, Inc. (1.45%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-62.66%), greater than Enliven Therapeutics, Inc. (-29.46%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Gossamer Bio, Inc. (-127.28%), greater than Tarsus Pharmaceuticals, Inc. (-55.86%), greater than LianBio (-21.53%), greater than Aldeyra Therapeutics, Inc. (-43.01%), greater than Travere Therapeutics, Inc. (-541.59%), greater than Passage Bio, Inc. (-72.53%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than TCR2 Therapeutics Inc. (-71.90%), greater than Harpoon Therapeutics, Inc. (-19.66%), greater than Alector, Inc. (-108.77%),
Company | ROE | Market cap |
---|---|---|
7.21% | $55.03M | |
-32.99% | $107.54M | |
-108.68% | $949.12M | |
21.51% | $255.09M | |
0% | $342.68M | |
1.45% | $209.76M | |
-35.28% | $223.97M | |
-62.66% | $465.23M | |
-29.46% | $1.13B | |
-53.12% | $941.76M | |
-155.80% | $89.84M | |
-178.68% | $11.28M | |
-64.55% | $57.32M | |
-127.28% | $191.23M | |
-55.86% | $2.07B | |
-21.53% | $34.47M | |
-43.01% | $283.16M | |
-541.59% | $1.49B | |
-72.53% | $40.24M | |
-68.08% | $123.92M | |
-71.90% | $58.11M | |
-19.66% | $865.08M | |
-108.77% | $181.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eton Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eton Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Eton Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Eton Pharmaceuticals, Inc. (ETON)?
What is the highest ROE for Eton Pharmaceuticals, Inc. (ETON)?
What is the 3-year average ROE for Eton Pharmaceuticals, Inc. (ETON)?
What is the 5-year average ROE for Eton Pharmaceuticals, Inc. (ETON)?
How does the current ROE for Eton Pharmaceuticals, Inc. (ETON) compare to its historical average?